Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30043401 | 0.99 | DDB1 (0.58) | DDB1CRBNADORA3ADORA2AADORA2B | |
| Hydrochloric Acid SCHEMBL30043186 | 0.92 | DDB1 (0.58) | DDB1CRBNPOLBKMT2A | |
| SCHEMBL24764703 | 0.91 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL21071373 | 0.91 | DDB1 (0.60) | DDB1CRBNPOLBKMT2A | |
| SCHEMBL22836090 | 0.91 | DDB1 (0.64) | DDB1CRBNITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL30043700 | 0.90 | DDB1 (0.63) | DDB1CRBNITGB3ITGA2B | |
| SCHEMBL26635000 | 0.90 | DDB1 (0.63) | DDB1CRBNITGB3ITGA2B | |
| SCHEMBL21071101 | 0.90 | DDB1 (0.58) | DDB1CRBNPOLBKMT2A | |
| SCHEMBL23832588 | 0.89 | CRBN (0.67) | DDB1CRBN | |
| Hydrochloric Acid SCHEMBL30042940 | 0.89 | DDB1 (0.58) | DDB1CRBNPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | DDB1 3837/4885CRBN 183/4885ADORA3 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.